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 Aldehyde oxidase (AO) is a cytosolic molybdenum-containing hydroxylase.  It is 
found in the highest concentrations in the liver and intestines of humans and other 
mammals but is also expressed in a variety of other organs, such as the kidney, lung and 
brain.  The aim of this research was to investigate AO activity in bovine kidney and to 
determine if bovine kidney AO contributes to the metabolism of xenobiotics.   Five 
known substrates for AO were evaluated to quantify AO activity in the kidney and these 
values were then compared to rabbit liver and bovine liver activities.  Experiments with 
two known inhibitors of AO, menadione and methanol, were performed to help verify 
that the activity found in the partially purified enzyme preparations were catalyzed by 
AO.   For all substrates evaluated, rabbit liver showed the highest activity followed by 
bovine liver and then bovine kidney.  No measurable activity for the bovine kidney 
enzyme was observed with phenanthridine or methotrexate as substrates.  However, 
bovine kidney AO catalyzed the oxidation of benzaldehyde, phenazine methosulfate and 
N
1
-methylnicotinamide.  In conclusion, low levels of aldehyde oxidase activity were 
measured in the bovine kidney using xenobiotic substrates. 
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CHAPTER I 
INTRODUCTION 
Aldehyde oxidase (AO; EC 1.2.3.1) and xanthine oxidase (XO; EC 1.2.3.2) are 
cytosolic enzymes belonging to a class of enzymes termed molybdenum hydroxylases 
(1).  Molybdenum hydroxylases are found in nearly every organism from humans to 
bacteria and have been determined to be present in a number of various tissues.  Xanthine 
oxidase occurs in high concentration in cow’s milk and in the lactating mammary gland, 
whereas aldehyde oxidase is expressed predominantly in the liver of mammals.  
However, many other tissues have been shown to contain AO and XO.  Xanthine oxidase 
has been detected in the liver, small intestine, forestomach, oral and nasal cavities, 
esophagus, tongue, uterus, epidermis and other tissues and organs.  Except for the 
epidermis, aldehyde oxidase has been found to be similarly distributed (2).    
Many species have been shown to express aldehyde oxidase and xanthine oxidase  
activity.  Aldehyde oxidase has been found in the livers of bovine and rabbit (as our 
research also shows), as well as rat, mouse, hog, guinea pig, monkey, hamster, and the 
livers of fish.  No aldehyde oxidase activity has been detected in birds or dogs (2).  The 
highest activity for AO was found in monkeys and humans.  This is followed by hamster, 
rabbit, guinea pig, rat and mouse (2).  In addition, aldehyde oxidase has also been found 
to be prevalent amongst crustaceans, mollusks, and insects (3).  Xanthine oxidase has
 
 
2 
 
also been found in the livers of a wide variety of species including humans, rodents, and 
bovines.  Four of the best characterized  molybdenum hydroxylases include xanthine 
dehydrogenase (XDH), aldehyde oxidoreductase (AOR), aldehyde oxidase (AO) and 
xanthine oxidase (XO), the latter two of which this research is focused.  Of the four 
enzymes listed above, all are found in eukaryotes except for AOR, which is a bacterial 
enzyme referred to as MoP for molybdenum protein (4).    
 It is an objective of this research to partially purify and measure the activity of 
aldehyde oxidase and xanthine oxidase in bovine kidney and to compare these values to 
the activities found in bovine liver and rabbit liver.   Past research has shown the 
presence of the aldehyde oxidase protein in various bovine tissues including that of the 
kidney as determined by Western blot analysis.  In a bovine tissue distribution 
experiment by Marco Li Calzi et. al. (5) significant amounts of the aldehyde oxidase 
protein were found in the liver and the lung of the cow, followed by the spleen.  Although 
at much lower levels the eye, kidney, thymus, testis, duodenum, heart, and esophagus 
also showed detectable amounts of the bovine aldehyde oxidase protein.   
 The kidney makes a good candidate for this type or research due to the fact that it 
is a potential site for xenobiotic metabolism.  The kidney is a complex organ with 
numerous biological roles but has received considerably less attention than the liver with 
respect to xenobiotic metabolism.  The kidney is discussed in more detail in Chapter 2 of 
this thesis.  The substrates used to evaluate aldehyde oxidase activity in the bovine 
kidney and liver include the xenobiotics: phenanthridine, benzaldehyde, and methotrexate 
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(a drug of pharmacological significance, MTX), the endogenous compound; N
1
-
methylnicotinamide (NMN) and another well known aldehyde oxidase substrate; 
phenazine methosulfate (PMS).  All activity measurements of this research project were 
performed on the partially purified enzymes.  Phenanthridine is a popular choice 
substrate for aldehyde oxidase activity measurements and has been used by other 
researchers for the determination of aldehyde oxidase activity in bovine liver (5).  
Xanthine, the well known endogenous substrate for xanthine oxidase, is used as the sole 
substrate for activity measurements of XO for this research project.  It is also the 
predominant substrate used by other researchers for xanthine oxidase activity 
measurements.   
 The fact that most metabolic reactions are taking place in the liver makes this 
organ a good standard for comparison to other tissues, such as the kidney.  Valuable 
comparisons can be made within the same species or across species.   This research 
project shows activity comparison data of the bovine kidney to within the species (bovine 
liver) and across species (rabbit liver).   Due to its availability and high activity levels as 
determined using a number of substrate types, rabbit liver aldehyde oxidase is the 
prototypical enzyme and often serves as a standard for aldehyde oxidase activity 
measurements.  Rabbit liver AO is also the most extensively studied of the enzymes (6). 
It is well established that liver aldehyde oxidases of many species are able to 
catalyze the metabolism of various xenobiotics.  XO and AO have shown their highest 
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activities in the liver.   Comparing the activities of AO and XO found in the kidney to the 
hepatic tissues will aid in understanding if the levels found in the kidney are significant 
and therefore contribute to the oxidation of xenobiotics.  Another key question to be 
addressed in the research is whether the kidney enzymes (AO and XO) show the same 
specificity towards substrates as the corresponding liver enzymes. 
The ultimate objective of this research is to obtain valuable information as to 
whether aldehyde oxidase from the extrahepatic tissue bovine kidney contributes to the 
oxidation of, and therefore, the metabolism of xenobiotics.  Xenobiotics are compounds 
that are foreign to the body, which include drugs such as antibiotics, pollutants such as 
dioxins, and other substances that are not normally present in the body.  Xenobiotic 
metabolism is the series of metabolic pathways that change the chemical structure of 
xenobiotics.  These reactions often act to detoxify poisonous chemical compounds.  
Sometimes, however, the product of xenobiotic metabolism can be the cause of toxic 
effects (7).  Such is the case with methotrexate, our primary xenobiotic of interest for this 
research project.  Methotrexate is a clinically important anti-cancer drug and is one of the 
few drugs that are significantly oxidized by aldehyde oxidase.  Its oxidative product, 7-
hydroxymethotrexate is cytotoxic.  This is discussed in more detail in Chapter 2 of this 
research paper.   
In all known cases, aldehyde oxidase exists exclusively in its oxidase form (1).  
However, mammalian xanthine oxidase (XO; EC 1.1.3.22) is involved in an inter-
conversion from xanthine dehydrogenase (XDH; EC 1.1.1.204) by oxidation of 
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sulfhydryl residues (that is, cyteines to cystines ) (8) by actions of proteases (limited 
proteolysis) (8), and upon oxidative stress or other conditions including purification.  
When the enzyme is in an oxidized state it exists as the oxidase form, when it is in a 
reduced state it exists as the dehydrogenase form.  The two forms of this enzyme are 
collectively termed xanthine oxidoreductase (XOR) and this term is used throughout this 
thesis as it applies.  Xanthine oxidoreductase (XOR) is the prototypical molybdenum 
hydroxylase and therefore serves as a structural and mechanistic model for the less 
studied aldehyde oxidase.   XOR, as purified from bovine milk, is the most frequently 
studied enzyme of this family and serves as a standard for the large class of 
molybdenum-containing enzymes (9).  This is mostly due to the presence of XOR in 
cow’s milk which is readily obtained and is commercially available on a gram-scale 
basis.  Xanthine oxidoreductase was first purified over 60 years ago (10) and continues to 
be purified or partially purified for a variety of research purposes.   
In the non-mammalian species chicken, xanthine dehydrogenase is stable and 
does not convert to the oxidase form (8) even though the species is still a eukaryotic 
system.  As a matter of fact, even within the mammalian tissue, XDH is believed to be 
the predominant form of the enzyme (8) under non-pathological (normal) conditions.  
The difference between the two forms is largely based on the electron acceptor it utilizes 
for its catalytic activity.  XO transfers reducing equivalents to O2, where as XDH transfers 
them predominantly to NAD
+
 and to a much lesser extent oxygen as well (1).   
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 Aldehyde oxidase and xanthine oxidase are very closely related enzymes (2) in 
terms of their general chemical structure, biochemical characteristics, and amino acid 
sequences (11).  These two enzymes are complex metalloflavoenzymes that contain one 
flavin adenine dinucleotide (FAD), two non-identical iron sulfur centers [2Fe-2S], and a 
molybdenum cofactor as prosthetic groups (8).  Though xanthine oxidase and aldehyde 
oxidase are extremely similar in their protein structure and prosthetic group composition, 
they are surprisingly different in their substrate specificities (12).  In general, these 
molybdoflavoenzymes, sometimes referred to as MFE’s (13), catalyze the oxidation of 
N-heterocycles via nucleophilic addition reactions (2).  Aldehyde oxidase catalyzes the 
oxidation of aldehydes and nitrogeneous heterocyclic xenobiotics like methotrexate and 
cyclophosphamide as well as the oxidative metabolism of a variety of endogenous 
compounds like retinaldehyde, pyridoxal, and N
1
-methylnicotinamide (2).  The absolute 
primary physiological function of aldehyde oxidase is yet to be determined.  Also the 
physiological importance of aldehyde oxidase’s role in aldehyde oxidation is in question 
due to the fact that the Michaelis constant (Km) for aldehyde oxidase and xanthine 
oxidase is higher for aliphatic aldehydes than it is for another mammalian enzyme, 
aldehyde dehydrogenase (ALDH) [EC; 1.2.1.3].  Aldehyde dehydrogenase, which is not a 
member of the molybdenum hydroxylase family, is thought to be the main enzyme for 
aldehyde oxidation in mammals.  ALDH, with its wide substrate specificity, removes a 
variety of aldehydes which are consumed in the diet or formed during xenobiotic 
metabolism (14).  Because of this, aldehyde dehydrogenase is often considered a 
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detoxification enzyme (14).  Xanthine oxidase’s physiological role is mainly in purine 
catabolism in which it catalyzes the oxidation of hypoxanthine to xanthine and then to 
uric acid (2).  However, it also contributes to oxidative metabolism of certain xenobiotics.  
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CHAPTER II 
BACKGROUND    
The Molybdenum Metal 
 Molybdenum (Mo) is a redox-active transition element that is essential for most 
biological systems as it is required by enzymes that catalyze basic metabolic reactions in 
the carbon, nitrogen, and sulfur cycles (4).  Molybdenum belongs to the second row of 
the periodic table and is the only element of that row that is required to grow and sustain 
life for a variety of organisms (4).  Molybdenum is found in a wide range of 
metalloenzymes, however is not an abundant element of the earth or the earth’s crust as 
would be thought by its demand (15).  It is however, very abundant in the oceans in the 
form of the dianionic molybdate ion [MoO4]
-2
 (Fig. 1) at concentrations of about 10 
micrograms per liter (16).    
 
Figure 1.  The Molybdate Ion.  A tetrahedral structure containing an oxyanion with 
molybdenum in its highest oxidation state of +6.
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 It is in this form by way of complex biological systems that the uptake of 
molybdenum into the cells takes place.  Over the past ten years, the number of 
molybdenum enzymes identified has grown to a point where a classification system based 
on active site structure has been developed (17).  The enzymes have been grouped into 
three families;  the xanthine oxidase (XO), sulfite oxidase (SO), and dimethylsulfoxide 
(DMSO) reductase families (9).   AO and XO both belong to the xanthine oxidase family 
along with XDH and AOR (4). 
 Molybdenum is found in a mononuclear center in all molybdoenzymes except for 
nitrogenase, where it is part of a multinuclear cluster with seven iron atoms (17).  More 
than 50 different mononuclear molybdenum enzymes in nature have been reported to 
date, which are mostly from bacterial origin (18).  A diverse series of metalloenzymes 
containing molybdenum occur in plants, animals, fungi, and bacteria (18). 
 
The Cofactor and Active Site (Moco) 
 Molybdenum itself is biologically inactive unless bound to a tricyclic pterin 
compound where it then forms the molybdenum cofactor (Moco).  Attached to the 
tricyclic pterin core of Moco is a pyran ring.  Moco is located at the active site of all 
molybdenum enzymes (18).  The pterin structure coordinates to the molybdenum metal 
by way of an enedithiolate side chain (19).  The function of the cofactor appears to be the 
transfer of electrons out of the molybdenum center after the oxidation reaction has taken 
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place.  This results in the reduction of molybdenum from Mo(VI) to Mo(IV) (19).   A 
proposed electron transfer sequence proceeds as shown below (Fig. 2) (20) where Fe/S I 
and Fe/S II are two distinct iron-sulfur centers.  However, this scheme implies a linear 
sequence of flow and is not necessarily the case for all systems.  
 
Mo            Fe/S I          Fe/S II          FAD 
Electron Movement      
Figure 2. Electron Transfer Sequence.  Proposed sequence of electron flow out of the 
molybdenum center. 
  
 The cofactor (Fig. 5) is formed by the combination of a molydopterin molecule 
(Fig. 4) and the active site structure (Fig. 3) through a series of biosynthetic reactions.    
The molybdenum hydroxylases, aldehye oxidase and xanthine oxidase, contain an active 
site that is believed to be in a five-coordinate complex with two enedithiolate ligands of 
the molybdopterin cofactor, one oxo group, one sulfide group, and one hydroxyl or water 
molecule.  This coordination results in a square pyramidal geometric structure and is the 
site for substrate binding and enzyme inhibition (21).   
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Figure 3.  Active Site Structure for the Xanthine Oxidase Family of Enzymes. Square 
pyramidal structure with Mo in the +6 oxidation state.  Identical for xanthine oxidase and 
aldehyde oxidase enzymes. 
 
 
 
Figure 4.  Structural Model for Pyranopterin Molecule (Molybdopterin).  The 
pyranopterin structure for molybdenum hydroxylase enzymes, an organic ligand in the 
monophosphate form. 
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Figure 5.  Moco (Molybdenum Cofactor).  The active site structure attached to the 
pyranopterin compound by way of two enedithiolate side chains to produce the 
molybdenum cofactor (Moco). 
 
AO/XO Enzymes 
 Aldehyde oxidase and xanthine oxidase are mononuclear molybdenum enzymes 
belonging to a family termed molybdenum hydroxylases.  Molybdenum hydroxylases 
embody the largest group of mononuclear molybdenum enzymes with more than 20 
being identified (17).  As of 2005, the crystal structures of three molybdenum 
hydroxylases have been determined (19).  They include xanthine oxidoreductase from 
Bos taurus, xanthine dehydrogenase from Rhodobacter capsulatus and aldehyde 
oxidoreductase from Desulfovibrio gigas.  In addition, the crystal structure of carbon 
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monooxide dehydrogenase from Oligotropha carboxidovorans which catalyzes the 
oxidation of a different type of reaction (carbon monoxide (CO) to carbon dioxide (CO2)) 
has been determined.  CO dehydrogenase bears a strong structural homology to the 
molybdenum hydroxyalses  (Fig.6) (19).  Aldehyde oxidoreductase from Desulfovibrio 
gigas was the first mononuclear enzyme whose structure at 2.25Å resolution was 
determined using x-ray crystallography (17).  All of these enzymes bear the same overall 
architecture (19).   
 The crystal structures of the molybdenum hydroxylase enzymes show that the N-
terminus contains two iron-sulfur clusters [2Fe-2S] in different domains and, except for 
aldehyde oxidoreductase from Desulfovibrio gigas, FAD in a third domain.  The binding 
portion of the molybdenum atom of the enzyme is at the C-terminus with the 
molybdenum center near the intersection of two stretched domains that form about a 90
o
 
angle (19).   
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Xanthine oxidoreductase from Bos Taurus: 
[2Fe—2S] [2Fe—2S] FAD Mo  
domain 1 
Mo 
domain 2 
 
Xanthine dehydrogenase from Rhodobacter capsulatus: 
[2Fe—2S] [2Fe—2S] FAD Mo  
domain 1 
Mo 
domain 2 
Subunit A Subunit A Subunit A Subunit B Subunit B 
 
Aldehyde oxidoreductase from Desulovibrio gigas: 
[2Fe—2S] [2Fe—2S]  Mo  
domain 1 
Mo 
domain 2 
 
CO dehydrogenase from Oligotropha carboxidovorans: 
[2Fe—2S] [2Fe—2S] FAD Mo  
domain 1 
Mo 
domain 2 
Subunit A Subunit A Subunit B Subunit C Subunit C 
 
 
Figure 6.  Schematic Representation of the Molybdenum Hydroxylase Homologies.  In 
xanthine dehydrogenase the iron-sulfur centers and the FAD constitute one subunit and 
the molybdenum binding portion a second subunit.  In the CO dehydrogenase , the iron-
sulfur centers are together in one subunit,  the FAD in a second subunit and the 
molybdenum center in a third subunit.  The FAD domain is absent in the aldehyde 
oxidoreductase enzyme.  The Mo domain 1 and 2 indicate that the molybdenum center is 
at the interface of two elongated domains that lie across one another. 
 
Hille, R. Molybdenum-containing hydroxylases. Arch. Biochem. Biophys. 2005, 433, 
107-116. 
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 In general, mononuclear molybdenum enzymes catalyze oxygen atom transfer 
reactions (21).  In the case of molybdenum hydroxylases, this is done through the 
hydroxylation of carbon centers where the oxygen atom incorporated into the product 
ultimately comes from water and not from molecular oxygen (O2), which is in contrast to 
a monooxygenase reaction (19).  These enzymes catalyze the hydroxylation reactions of 
substrates containing N-heterocycle or aldehyde functional groups (Fig. 7). 
 
 
Figure 7.   Oxygen Atom Transfer Reaction by Molybdenum Hydroxylases.  General 
oxidation reaction catalyzed by molybdenum hydroxylases producing an oxidized 
substate and two reducing equivalents.  
 
 This two-electron redox reaction takes place at the molybdenum center.  During 
the course of the reaction the molybdenum atom is reduced from Mo(VI) to Mo(IV) after 
substrate interaction via the molybdopterin cofactor.  The overall reaction generates two 
reducing equivalents that are transferred to an external electron acceptor via an electron 
transfer system introduced by other cofactors present in the enzyme (21).  This is in 
contrast to the cytochromes P450 hydroxylation systems that rather consume the reducing 
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equivalents (9).  For the case of an aldehyde substrate the product is a carboxylic acid 
(Fig. 8). 
 
Figure 8.  Oxygen Atom Transfer Reaction Involving an Aldehyde.  General oxidation 
reaction catalyzed by molybdenum hydroxylases in which the oxidation of an aldehyde is 
converted to its corresponding carboxylic acid producing with it two reducing 
equivalents.  
 
AO/XO Mechanism of Action 
 The mechanism of action (Fig. 9) by which molybdenum enzymes catalyze 
oxidation reactions has been a focus of research for many years (22).  The reality that 
molybdenum hydroxylases use water and not molecular oxygen as the source of oxygen 
incorporated into the product has made this mechanism extremely interesting (22).  Due 
to the increasing availability of crystal structures for some molybdenum hydroxylases, 
the chemistry of the mechanism is now better understood (22).   
 Xanthine oxidase has been studied for more than 40 years and its mechanism of 
action has been unclear for most of that time (9).  The close relationship between AO and 
XO/XOR implies a common mechanism of action for these two enzymes.  There have 
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been two proposed mechanisms for the xanthine oxidoreductase enzyme.  The two 
mechanisms differ in the source of the labile oxygen atom.  The alternate mechanisms 
illustrate either the oxygen from the oxo group (Mo=O) or the oxygen from the hydroxyl 
group (Mo-OH) as the catalytically labile (least stable) oxygen from the active site of the 
enzyme (23).  The oxygen used as the labile one defines which oxygen atom is ultimately 
transferred to the substrate (17).  Until about 1996, most researchers believed it was the 
Mo=O group that donated its oxygen to the substrate (17) as an electrophile and the oxo 
ligand being revived from a water molecule (24).  However, electron spin echo (ESEEM) 
and electron-nuclear double resonance (ENDOR) studies of the Mo(V) intermediate of 
the reaction have provided evidence that it is the oxygen atom from the Mo-OH moiety 
that is incorporated into the substrate (22).  Subsequent experiments from other 
researchers have agreed with the evidence that supports the Mo-OH group as containing 
the labile oxygen.  Since this is the case, only the agreed upon mechanism will be shown 
in this thesis using xanthine as the example substrate.   This oxygen atom transfer 
reaction begins with an active site base abstracting the hydrogen from the Mo-OH group.  
The group then proceeds to initiate nucleophilic attack at the C-8 position of the xanthine 
substrate (22).  The C-8 position on xanthine is the site of attack due to it being adjacent 
to two ring nitrogens and therefore the more electropositive carbon atom.  At the same 
time, a hydride transfer is taking place from the C-8 position on the xanthine substrate to 
the Mo
VI
=S group.  This then leads to a reduction of the molybdenum atom from +6 to a 
+4 oxidation state.  Loss of the proton from the sulfur and electron transfer produces 
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transient formation of the Mo(V) intermediate which has a very rapid EPR signal.  Water 
then enters the reaction, the oxidation product dissociates, and its position on the 
molybdenum center is replaced by a water or hydroxyl group.  This then results in an 
increase in oxidation state of the molybdenum metal from Mo(V) to Mo(VI) (17).  The 
conversion of aldehydes to the corresponding carboxylic acid proceeds in like manner via 
a base-assisted nucleophilic attack of the Mo-OH on the substrate carbonyl with 
concomitant hydride transfer to the Mo=S (Fig. 10). 
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Figure 9.  The Reaction Mechanism for Xanthine Oxidase.  Active site base abstracts 
proton form the Mo-OH group which then undertakes nucleophilic attack on the C-8 
position of the xanthine substrate with concomitant hydride transfer to Mo=S.  Formation 
of paramagnetic species followed by displacement of product by hydroxide form solvent  
returns active site to original state.    
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Figure 10.  A General Reaction Mechanism for the Aldehyde Oxidase Enzyme.  A base-
assisted nucleophilic attack of the Mo-OH on the substrate carbonyl with concomitant 
hydride transfer to the Mo=S which leads to the conversion of the aldehyde to its 
corresponding carboxylic acid. 
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Characterization of AO/XO 
 Aldehyde oxidase and xanthine oxidase are both complex metalloflavoproteins.  
They are homodimers due to the existence of two identical subunits.  Each subunit has a 
molecular weight of about 145,000 Daltons (145kDa) for a total of about 290,000 
Daltons (290kDa) per dimer (2).  However the weight can vary according to species (8).  
Each monomeric subunit consists of four redox centers which include one molybdenum 
atom contained in a molybdopterin molecule (85kDa), one FAD molecule (40kDa), and 
two non-identical iron-sulfur [2Fe-2S] groups (20kDa) identified as Fe/S I and Fe/S II 
(2).  This makes each enzyme contain eight iron atoms and eight sulfur atoms.  The 
geometry and ligation of molybdenum in AO and XO are identical. 
 In vivo, molecular oxygen serves as the electron acceptor for aldehyde oxidase.  
Xanthine oxidoreductase, on the other hand, exists primarily in the dehydrogenase form 
and its electron acceptor is NAD
+
.  Those enzymes function by being alternately reduced 
by the substrate and then reoxidized by their respective electron acceptors.  In vitro, 
potassium ferricyanide (K3[Fe(CN)6]) and 2,6-dichloroindophenol (DCIP) have proven to 
be effective artificial electron acceptors for these enzymes, replacing molecular oxygen 
(25). 
 Within the enzyme structure, flavin adenine dinucleotide (FAD) is the site where 
electrons are transferred to molecular oxygen where they produce the superoxide anion 
(O2·-) in XOR and AO catalysis, or to NAD
+
 to form NADH in XDH catalysis (18).  
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However, XDH can utilize both O2 and NAD
+
 as an electron acceptor.  XO and AO are 
known to only use molecular oxygen as an electron acceptor in vivo (18).  AO has been 
known to produce hydrogen peroxide (H2O2) as well as the superoxide anion (18).  The 
ability of AO and XOR to produce the reactive oxygen species H2O2 and O2·- has 
demonstrated their role in diseases such as ischemia-reperfusion injury and ethanol 
hepatotoxicity (1).  The reduction of oxygen leads to the production of the reactive 
oxygen species (ROS) O2
.-
 and H2O2.  Especially with respect to XOR, this has become a 
critical issue of interest to researchers due to its apparent role in oxidative stress (2).  
However, studies have found that the oxidation of aldehydes by AO in the presence of O2 
have also resulted in the production of large amounts of O2
.-
 and H2O2 (11).  Oxidative 
stress is associated with pathological conditions including Alzheimer’s disease, diabetes, 
rheumatoid arthritis, cancer and other such diseases.  Oxidative stress is also proposed to 
be one of the main factors contributing to the biological symptoms of aging (26).  
Biologically speaking, oxidative stress is an imbalance between the production of 
reactive oxygen species and a biological systems ability to quickly detoxify the reactive 
intermediates or easily repair the damage that was caused.  Continued oxidative stress 
causes damages to the entire cell, proteins, lipids and DNA (27).  Chemically speaking, 
oxidative stress is a significant increase in cellular reduction potential (becoming less 
negative) or a large decrease in the reducing capacity of the cellular redox couples (27). 
 When molecular oxygen is utilized as the electron acceptor in AO and XOR 
catalyzed oxidations, the oxygen undergoes a two-electron reduction producing H2O2 and 
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a slower one-electron reduction to produce  O2·- (1, 11, 28).  These two pathways are 
illustrated below in two distinct kinetic phases (Fig. 11).   In both phases, the reduction of 
O2 occurs at the FAD site (1).  The reaction in the case of XDH, where the electron 
acceptor is NAD
+ 
is also shown in figure 11. This pathway is a two-electron process (28). 
 
 
Figure 11.  Reduction Pathways Occuring in XOR/AO and XDH.  The three different 
reduction pathways occurring at the FAD site within the enzyme structure.  The O2 
reactions occur within the AO and XO enzyme structure.  The NAD
+
 reaction occurs 
within the XDH enzyme structure. 
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 Molybdenum hydroxylases generally catalyze oxidation reactions that largely 
involve nucleophilic attack of electrophilic carbons including those of aldehyde groups 
and carbons of N-heterocycles that are para to or adjacent to the ring-nitrogen.  The 
carbons adjacent to the ring-nitrogen in N-heterocycles are normally the most 
electropositive, eg. in pyrazine, purine, pyrimidine, quinoline, pyridine and  pteridine (2).   
  Aldehyde oxidase and xanthine oxidase catalyze the oxidations of many different 
N-heterocyclic compounds as well as aliphatic and aromatic aldehydes to their 
corresponding carboxylic acids (14).  As indicated earlier, AO and XO are very closely 
related enzymes in terms of their structural properties.  Despite their ability to oxidize the 
same class of substrates and their structural similarities, AO and XO vary in their 
substrate specificities and their response to inhibitors (11, 18).  For this reason, it is 
experimentally possible to differentiate between the enzymes by measuring the activities 
obtained by reacting them with different substrates or by subjecting the oxidation 
reactions to different inhibitors.  For example, the well known endogeneous substrate 
xanthine is converted to uric acid by XO but AO is incapable of catalyzing this reaction.  
On the other hand, AO easily converts N
1
-methylnicotinimide to its pyridone derivative 
but XO does not. 
 Despite its name, aldehyde oxidase not only oxidizes aldehydes but also catalyzes 
the hydroxylation of aromatic azaheterocycles possessing a –CH=N- moiety such as 
phthalazine and purine or aromatic and non-aromatic charged heterocycles with a  
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–CH=N
+
 group like N
1
-methylnicotinamide and N-methylphthalazinium (11).  Xanthine 
oxidase has a smaller substrate specificity range than AO and is mostly involved in the 
oxidation of purines (18).  The accepted physiologic role of XOR is catalyzing the 
oxidation of hypoxanthine to xanthine and ultimately to uric acid (2).  Besides xanthine, 
XO also catalyzes the oxidation of a number of xenobiotics, such as the conversion of 6-
deoxyacyclovir to acyclovir (Fig. 12). 
 
 
Figure 12.  The Activation of 6-Deoxyacyclovir by Xanthine Oxidase.  The metabolism 
of a xenobiotic by xanthine oxidase. 
  
 AO and XOR are both important in the metabolism of xenobiotics and 
endogeneous compounds (2, 8).   Two notable endogenous substrates for AO include 
retinaldehyde and pyridoxal (2).  Retinaldehyde is the principle component of visual 
pigments and for this reason aldehyde oxidase has been suggested to be an important part 
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of the overall visual process since it catalyzes the biotransformation of this aldehyde to its 
corresponding carboxylic acid, retinoic acid, which is the active form of vitamin A (Fig. 
13) (5).  Because of this it has been suggested that the physiological function of aldehyde 
oxidase appears to be the synthesis of retinoic acid from retinal (29).  It was once 
reported that retinaldehyde is oxidized to retinoic acid by rabbit liver retinal oxidase (EC 
1.2.3.11).  However, in a report by S. Tomita et. al. (29) retinal oxidase was found to be 
identical to aldehyde oxidase.   Pyridoxal is also converted to its corresponding 
carboxylic acid by AO to 4-pyridoxic acid (Fig. 14).   
 
 
Figure 13.  Metabolism of Retinal Catalyzed by Aldehyde Oxidase.  Conversion of 
retinaldehyde to its corresponding carboxylic acid by aldehyde oxidase.  Proposed to be a 
primary physiological role for aldehyde oxidase. 
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Figure 14.  Metabolism of Pyridoxal Catalyzed by Aldehyde Oxidase.  Oxidation of 
pyridoxal to its corresponding carboxylic acid catalyzed by aldehyde oxidase. 
  
 With respect to the rate of aldehyde oxidation, aldehyde oxidase has generally 
been shown to achieve faster rates of conversion than xanthine oxidase.  A good example 
is the aromatic aldehyde vanillin which has been shown to be rapidly converted to its 
metabolite vanillic acid by AO but only slowly converted to its metabolite by XO (Fig. 
15) (14).  In addition, the molybdenum site in AO may be more accessible to solvent than 
the molybdenum site in XO as determined by the fact that cyanide, a compound that 
renders both enzymes inactive by covalent modification, works faster in AO than XO.    
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Figure 15.  Metabolism of Vanillin to Vanillic Acid.  Conversion of vanillin to its 
corresponding carboxylic acid catalyzed by either aldehyde oxidase or xanthine oxidase. 
Aldehyde oxidase results in a faster conversion. 
 
 AO and XO have many common substrates as well.  AO, like XO, can also 
catalyze the oxidation of purines and in some cases with higher activity than by XO (28).  
For example, 6-mercaptopurine is oxidized by AO to 6-mercaptopurin-8-one and by XO 
to 6-mercaptopurin-2-one (2).  XO ultimately converts this to 6-thiouric acid (Fig. 16). 
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Figure 16.  The AO and XO Conversion of 6-Mercaptopurine.  The oxidation of 6-
mercaptopurine, a common substate for AO and XO, to different oxidative products. 
 
AO/XO Inhibitors 
AO and XO are often expressed together in mammalian tissues.  In order to 
increase the level of certainty that aldehyde oxidase is the enzyme responsible for the 
activity measured with its substrates, documented inhibitors of AO are useful in studies 
with crude tissue homogenate or partially purified enzyme fractions.  Measurements of 
activity in the presence and absence of inhibitors aid in confirming that the activity 
measured is truly from the enzyme of interest, that is in our case, aldehyde oxidase.  
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These studies also help to gain a better understanding of structural determinants that are 
critical for effective aldehyde oxidase inhibition and help determine the role inhibition 
plays in drug interactions (30). 
Menadione (1 x10
-5
 M), methanol (0.3 M), and potassium cyanide (1 x 10
-4
 M) 
have all been shown to inhibit the conversion of benzaldehyde to benzoic acid by human 
liver aldehyde oxidase by 55%, 67%, and 66% respectively (31).  It has been 
demonstrated that methanol inhibits the enzyme by attacking at or near the substrate-
binding site.  Menadione, on the other hand, inhibits by interfering with the reduction and 
reoxidation of the internal electron transport chain components and does not bind to the 
substrate binding site (31).  Cyanide and methanol have been determined to be just as 
effective at the inhibition of phenazine methosulfate (PMS) oxidation as they are for 
benzoic acid by human liver aldehyde oxidase but not menadione (31).  However, 
menadione is very effective at inhibiting PMS oxidation of rabbit liver aldehyde oxidase 
(31).  Menadione is a well established AO inhibitor and is often used as a standard for 
inhibition studies of AO catalyzed reactions.  Cyanide has been shown to be a potent 
irreversible xanthine oxidase family inhibitor.  Some classifications of Moco containing 
enzymes have been based on cyanide inhibition studies (4).  
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AO/XO Substrates 
N
1 
- methylnicotinamide (NMN) is a charged aromatic heterocycle containing a  
(–C=N
+
<) and is a stable iminium ion (28).  NMN is formed from nicotinamide by 
nicotinamide methyltransferase.  It is widely dispersed throughout the animal kingdom 
and has been discovered to be toxic to nerve tissue, however its oxidative products are 
not.  Aldehyde oxidase has been found to catalyze the oxidation of NMN to the non-toxic 
compounds N
1
-methyl-2-pyridone-5-carboxamide (2-PY) and N
1
-methyl-4-pyridone-3-
carboxamide (4-PY) (Fig. 17) with varying amounts according to species analyzed (32).  
NMN has been proven to be a good substrate for AO and is inactive as a substrate for 
XO.  Therefore NMN provides a specific probe for the presence of the aldehyde oxidase 
enzyme.   
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Figure 17.  Nicotinamide to Pyridone Derivatives of NMN.  Methylation of nicotinamide 
by nicotinamide methyltransferase followed by oxidation of N
1
-Methylnicotinamide by 
aldehyde oxidase to N
1
-methyl-2-pyridone-5-carboxamide (2-PY) and N
1
-methyl-4-
pyridone-3-carboxamide (4-PY). 
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Phenanthridine is an azaphenanthrene and has been detected in cigarette smoke, 
urban air particles, petroleum, shale oil, and coal products (33).   For this reason, 
phenanthridine is a xenobiotic that enters the body as a pollutant.  Phenanthridine and 
other azaphenanthrenes were mutagenic in Salmonella typhimurium in the presence of rat 
liver homogenate.  Phenanthridone is an oxidative product and minor oxidative 
metabolite of phenanthridine which was also found to be mutagenic in S. typhimurium.  
Phenanthridine is a good example of an uncharged xenobiotic substrate of aldehyde 
oxidase.  The oxidative product, phenanthridone, is a cyclic lactam substituted adjacent to 
a heterocyclic nitrogen atom (Fig. 18) (34). 
 
 
 
 
 
Figure 18.  Oxidation of Phenanthridine to Phenanthridone by Aldehyde Oxidase.  
Phenanthridine is a common substrate for aldehyde oxidase activity studies. 
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Methotrexate (MTX, 4-amino-N
10
-methylpteroyl-L-glutamic acid) formally 
known as amethopterin, is a pteridine compound.  A pteridine is an aromatic heterocycle 
containing –C=N<  moiety (28).  Methotrexate has been for a long time a common drug 
used in the treatment of leukemia in children and other adult and childhood cancers.  
More recently it has been a standard drug used for the treatment of psoriatic and 
rheumatoid arthritis (35).  It has been reported that this nitrogeneous heterocyclic 
xenobiotic is oxidized to its major metabolite 7-hydroxymethotrexate (7-OH-MTX) by 
rat liver aldehyde oxidase (36) and rabbit liver aldehyde oxidase (Fig. 19) (37).  When 
MTX is used for therapeutic purposes, the amount is extremely important since 7-OH-
MTX has been determined to be cytotoxic (36).   The low solubility of 7-OH-MTX in 
aqueous solutions is the cause of its potentially high cytotoxicity following either 
intermediate or high dose methotrexate therapy (38).  It was shown in monkey kidney 
following high dose MTX therapy that crystalline deposits of 7-OH-MTX had 
accumulated within the tubules thereby causing impairment of renal function (39).  Since 
it is the case that 7-OH-MTX is cytotoxic and has significant pharmacological effects, the 
hydroxylating activity of methotrexate to 7-hydroxymethotrexate becomes extremely 
important for the clinical administration of MTX. This then makes methotrexate a good 
candidate for AO activity assay studies by kidney aldehyde oxidase for the purpose of 
determining if AO may be contributing to the presence of 7-OH-MTX, therefore 
contributing to cytotoxicity of kidney cells. 
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Figure 19.  Oxidation of Methotrexate (MTX) to 7-Hydroxymethotrexate (7-OHMTX) by 
Aldehyde Oxidase. 
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Benzaldehyde is the simplest of aromatic aldehydes and is a well known 
xenobiotic substrate for aldehyde oxidase.  It is an important component of the scent of 
almonds and the primary component of bitter almond oil extract.  It can also be extracted 
from other natural sources such as cherry and apricot (40).  Therefore, benzaldehyde is a 
xenobiotic in that it is injested through various food stuffs.  On oxidation, benzaldehyde 
is converted to the odorless benzoic acid.  Benzaldehyde often serves as a standard for 
comparison to other substrates for the measurement of aldehyde oxidase activity.  
Benzaldehyde assays are very sensitive to the inhibitor menadione, which can be useful 
when xanthine oxidase is also present in partially purified enzyme preparations.   
Partially purified human liver aldehyde oxidase has been shown to have a high affinity 
toward the benzaldehyde substrate (41).  The aldehyde oxidase enzyme catalyzes the 
conversion of benzaldehyde to its corresponding carboxylic acid, benzoic acid (Fig. 20). 
 
 
 
Figure 20.  Oxidation of Benzaldehyde to Benzoic Acid.  Conversion of benzaldehyde to 
its corresponding carboxylic acid, benzoic acid, catalyzed by aldehyde oxidase. 
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Xanthine is an endogenous compound that is derived from guanine in a reaction 
catalyzed by guanase and is also formed when hypoxanthine is oxidized by either 
xanthine oxidase or xanthine dehydrogenase.  It is ultimately converted to uric acid by 
XO or XDH (Fig. 21) (23).   Xanthine is a purine base that is found in most body tissues 
and body fluids and is a product on the pathway of purine degradation (42).  Xanthine is, 
therefore, the most common substrate used for measurement of xanthine oxidase activity.   
 
 
 
Figure 21.  Hypoxanthine to Uric Acid by Xanthine Oxidase.  Oxidation of hypoxanthine 
to xanthine and then to uric acid, catalyzed by xanthine oxidase, the  primary 
physiological role of xanthine oxidase.   
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Phenazine methosulfate (PMS) serves as an electron acceptor for both the 
xanthine oxidase and aldehyde oxidase enzymes.  It is a dye that produces a red or yellow 
color when oxidized under aerobic incubation but a clear color in its reduced state (43, 
44).   PMS can also serve as a substrate for oxidation by aldehyde oxidase (Fig. 22) (43).  
The red oxidative product produces a significant rise in absorbance at a wavelength of 
520 nm, which provides a sensitive and reliable spectrophotometric assay for aldehyde 
oxidase activity (43).   PMS is an exception to the rule that oxidation normally takes 
place at the carbon atom adjacent to the ring nitrogen of an N-heterocycle structure, and 
this reaction is one of the few examples of oxidation by a molybdenum hydroxylase 
occurring in a benzenoid ring system. 
 
 
 
 
Figure 22.  Oxidation of Phenazine Methosulfate to 10-Methylphenazinone by Aldehyde 
Oxidase. 
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Renal and Hepatic Drug Metabolism 
The principle site of drug metabolism is the liver.  However, the kidneys, lungs, 
and gastrointestinal tracts are also important metabolic sites (45).  This makes the 
enzymatic reactions that take place in those extrahepatic organs also an important area of 
research.  The kidney tissue, though only representing about 0.5% of the body weight, 
receives between 20-30% of the cardiac output (46).  The kidney also accounts for 
approximately 10% of the oxygen consumption for the whole body.  The kidneys have 
many important physiological functions including filtering out urea, which is waste 
product carried in the blood, and concentrating it for excretion and maintaining and 
adjusting the pH of the blood (47).  It is also the main route for molybdenum excretion 
(48).  Other important physiological functions of the kidneys include maintenance of 
water and electrolyte balance, synthesis, metabolism and secretion of hormones.  In 
addition, the kidneys also play a major role in the excretion of drugs, hormones, and 
xenobiotics (49).  The role of the kidney in the metabolism of endogenous and exogenous 
compounds has not been given due research or attention.  Most of the research and 
acquired knowledge concerning xenobiotic metabolism is based on liver studies.  
However, it is becoming increasingly apparent that the kidney is actively involved in the 
metabolism of many drugs and xenobiotics.  As a matter of fact, it has even been shown 
that in some cases certain biotransformations occur faster in the kidney than in the liver; 
e.g., the glycination of benzoic acid (Fig. 23) (50).  
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Figure 23. Glycination of Benzoic Acid.  A biotransformation reaction that occurs faster 
in the kidney than in the liver. 
 
 
Experimental data accumulated over the last 20 years has shown a large capacity 
for the metabolism in the kidney that leads to activation or inactivation of many different 
compounds (49).  Additionally, the metabolites produced by the kidney may exert 
significant toxic effects.  Such is the case with the oxidation of methotrexate, which was 
discussed earlier.  The kidney has the ability to metabolize a large variety of substrates 
depending on their availability in the flow of blood.  The fact that the blood flows 
through the kidney carrying with it a variety of metabolites illustrates the importance of 
what enzymatic reactions may occur within that organ.  The oxidative metabolism in the 
kidney occurs mostly in the cortical segments of the nephron.   
Hepatic drug metabolism is already well established.  Enzymatic activity in the 
liver is extremely important since the liver is considered the body’s central metabolic 
clearing house.  The liver is responsible for maintaining the correct levels of nutrients in 
the blood for use by the brain, muscles, and other tissues.  All the nutrients absorbed by 
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the intestines except fatty acids drain directly into the liver.  The liver, being the body’s 
major metabolic processing unit, has a great many specialized biochemical functions 
which includes the detoxification of biologically active substances such as drugs, 
poisons, and hormones by a number of oxidation, reduction,  hydrolysis, conjugation, and 
methylation reactions (47).   
 
Molybdenum Hydroxylases vs. Monooxygenases 
 Cytochromes P450 are a very large family of heme-containing monooxygenase 
enzymes that are better known for metabolizing most of the xenobiotics and foreign 
chemicals in the body.  Like AO and XO, the P450 enzymes that are responsible for 
metabolizing xenobiotics show their highest activities in the liver, while they are also 
present in extrahepatic tissue including the lung and the kidney (26). 
 Cytochromes P450 generally catalyze electrophilic oxidation reactions whereas 
molybdenum hydroxylases catalyze nucleophilic oxidation reactions.  This then results in 
different oxidative products (2).  For example, caffeine is oxidized to 1,7-dimethyl-
xanthine by a P450 enzyme and to 1,3,7-trimethyluric acid by the AO enzyme (2).  In 
contrasting the reaction mechanisms for the two different systems,  molybdenum 
hydroxylases use water as the source of the oxygen atom incorporated into the product 
whereas the monooxygenase system uses molecular oxygen (O2).  Another important 
difference lays in the fact that molybdenum hydroxylases produce reducing equivalents 
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during the course of the oxidation reactions whereas P450 systems consume the reducing 
equivalents.  The two distinct reaction stoichiometries for the monooxygenases and 
molybdenum hydroxylases are illustrated below (Fig. 24) (19).  
 
 
 
 
Figure 24.  Cytochrome P450 vs. Molybdenum Hydroxylases.  Reactions showing the 
differences in these two systems. The source of oxygen is the primary difference in the 
reactions. 
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  There are some partnerships between the cytochrome P450’s and molybdenum 
hydroxylases.  For example, nicotine is oxidized to the nicotine iminium ion by the 
cytochrome P450 system and then on to cotinine by aldehyde oxidase (Fig. 25) (2). 
 
 
                                  
Figure 25.  Reaction Showing Partnership Between Cytochrome P450 and Aldehyde 
Oxidase.  First oxidation reaction catalyzed by cytochrome P450 enzyme followed by 
second oxidation reaction catalyzed by aldehyde oxidase.
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CHAPTER III 
EXPERIMENTAL 
Experimental Approaches 
There were two main approaches used to quantify aldehyde oxidase and xanthine 
oxidase activity in the partially purified enzymes; direct continuous and direct 
discontinuous assay methods.  Both methods utilized UV-Visible spectrophotometry to 
determine the absorbance change during substrate reactions.   The direct continuous 
assays, hereafter only referred to as continuous assays, allow for the production of a 
progress curve (Fig. 26) (51).
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Figure 26.  Illustration of an Enzyme-Catalyzed Reaction Curve.  The enzyme-substrate 
reaction deviates from a straight line after an extended period of time.  Not an actual 
curve from this research project.   
 
The use of progress curves allows for easy determination of initial rates (51).  For 
this research project, continuous assays were employed to evaluate the following six 
enzyme-substrate oxidation reactions:  AO – phenazine methosulfate, AO – N
1
-
methylnicotinamide, AO – phenanthridine, AO – benzaldehyde, AO – methotrexate, and 
XO – xanthine.  These assays were each performed using partially purified bovine liver, 
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bovine kidney, and rabbit liver enzymes.  Direct discontinuous assays, hereafter only 
referred to as discontinuous assays, give the extent of a reaction after a predetermined 
fixed time.  This involves stopping the reaction at the chosen time and directly reading 
the absorbances.  The discontinuous assay method was employed to evaluate the 
following four enzyme-substrate oxidation reactions:  AO – phenanthridine, XO – 
xanthine, AO – N
1
-methylnicotinamide, and AO – phenazine methosulfate.  These assays 
were performed using the partially purified bovine kidney enzyme only. 
 
Specific Activity Formulas 
 The specific activity formulas that are used to express the activity for enzyme 
assays for this research project uses the basis of the Beer’s Law (Fig. 27) and 
incorporates into it other factors that are necessary in determining the specific activity of 
an enzyme in micromoles per minute per milligram of protein.  These formulas (Fig. 28 
and Fig. 29) (52) are applicable to the two-minute initial rate continuous enzyme assays.  
Discontinuous assays use the straight forward Beer’s Law as seen in figure 27.  The 
specific activity formula for the initial rate continuous assays that utilize the natural 
electron acceptor, molecular oxygen, differ by a factor of 0.5 to the specific activity 
formula for the reactions that utilize ferricyanide as an artificial electron acceptor.  This is 
due to the fact that one mole of substrate is oxidized per two moles of ferricyanide that 
are reduced.  This is illustrated in figures 28 and 29.   
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Figure 27.  Beer’s Law.  Where A is the absorbance, ε is the molar absorptivity, b is the 
pathlength, and c is the concentration of the sample. 
 
 
 
Figure 28.  Specific Activity Formula (O2 as Electron Acceptor).   (∆A /
 
min) = 
absorbance change per minute (raw data generated by UV-Vis software);  mLFCV  = final 
cuvette volume in mLs;  mLOLPA  =  dilution factor in mLs if original Lowry Protein 
Assay solution was diluted prior to transferring to cuvette.  If no dilution was done to the 
original LPA solution then the value equals 1.  A value of 1 was used for all assays in this 
research project;  mLESI  =  mLs of enzyme solution transferred into the cuvette; 1000  =  
factor that arises because the units of activity are in µmols/min and because the molar 
absorptivity gives the concentration in M
-1
 and the cuvette volume is in mL. 
 
 
 
A = εbc 
[(∆A / min)
 
 / ε]  x  mLFCV  x  1,000  x  
(mLOLPA  /  mLESI) 
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Figure 29.  Specific Activity Formula (Ferricyanide as Electron Acceptor).  (∆A /
 
min)  = 
absorbance change per minute (raw data generated by UV-Vis software);  mLFCV  =  
final cuvette volume in mLs;  mLOLPA  =  dilution factor in mLs if original Lowry Protein 
Assay solution was diluted prior to transferring to cuvette.  If no dilution was done to the 
original LPA solution, then the value equals 1.   A value of 1 was used for all assays in 
this research project;  mLESI  =  mLs of enzyme solution transferred into the cuvette;  
1000  =  factor that arises because the units of activity are in µmols/min and because the 
molar absorptivity gives the concentration in M
-1
 and the cuvette volume is in mL;         
(1 mol / 2 mol) = factor arises due to the conversion for two mols of potassium 
ferricyanide that are reduced for each mole of substrate being oxidized. 
  
 Specific activities cannot be calculated from the raw data obtained from the thirty-
minute discontinuous assays since this assay is not measuring the initial reaction rates of 
the enzyme-substrate complex.  This type of assay only allows for the molarity of the 
oxidized product or total amount of product produced to be calculated.  This is 
accomplished by using the straight forward Beer’s Law equation that was discussed 
earlier.  In the case of the potassium ferricyanide method for the discontinuous assays, the 
Beer’s Law equation is divided by 2 because two moles of potassium ferricyanide are 
reduced for each mole of substrate being oxidized.   
[(∆A / min)
 
 / ε]  x  mLFCV  x  1,000  x  
(mLOLPA  /  mLESI )  x  (1 mol / 2 mol) 
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The Artificial Electron Acceptor Method 
 The use of artificial electron acceptors such as dichloroindophenol (DCIP) and 
potassium ferricyanide have proven to be effective replacements for the natural electron 
acceptor dioxygen for the monitoring of oxidation reactions that are catalyzed by 
aldehyde oxidase, xanthine oxidase and many other enzymes.  These electron acceptor 
compounds normally exhibit a maximum absorbance at high wavelengths that are 
normally within the visible range (380 nm – 780 nm).  The maximum absorbances are 
600 nm and 420 nm for DCIP and potassium ferricyanide, respectively.  
 One of the biggest benefits coming from the artificial electron acceptor method is 
that an enzyme activity experiment can be performed even when the max absorbance 
(λmax) is not known for a particular substrate.  This is in contrast to activity assays using 
oxygen as electron acceptor where the max absorbance must be known prior to 
performing the assay.  For the sake of the cost of research, time and money on 
experiments can be saved when using the artificial electron acceptor method since λ max 
and, therefore, molar absorptivities will not have to be experimentally determined if they 
are not already known.  There have been many substrate oxidations correlated to the 
reduction of these electron acceptor compounds.  These include aromatic and non-
aromatic aldehydes, heterocycles, purines, azaphenanthrenes, pteridines and others.  For 
this research project, the potassium ferricyanide assay was utilized to evaluate the 
following enzyme-substrate oxidation reactions:  AO – N
1
-methylnicotinamide, AO – 
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methotrexate, and XO – xanthine.  The following reaction illustrates the overall 
stoichiometry for the ferricyanide method (Fig. 30).  The reaction uses a general aldehyde 
as an example substrate though the stoichiometry is the same for all substrates.   
 
 
Figure 30.  The Ferricyanide Reaction Using an Aldehyde Substrate.  Ferricyanide is 
reduced to ferrocyanide during the course of the reaction. 
 
 As can be seen from the reaction above, the aldehyde or substrate, undergoes a 
two-electron oxidation which requires two successive one-electron reductions of 
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ferricyanide to produce ferrocyanide.  This spectrophotometric method monitors the 
coupled reduction of ferricyanide [Fe
+3
(CN)6] to ferrocyanide [Fe
+2
(CN)6] at 420 nm 
wavelength.  Many assays can be performed this way since ferricyanide shows reduction 
at the same wavelength regardless of the nature of the oxidative product and that the 
reduction of ferricyanide parallels the oxidation of the product.  This method worked well 
for our research because aldehyde oxidase and xanthine oxidase are both able to transfer 
electrons from oxidized substrates to electron acceptors other than oxygen.   
 
Enzyme Purification Procedure 
  Aldehyde oxidase and xanthine oxidase were partially purified to the ammonium 
sulfate fraction from the commercial tissues: bovine kidney, bovine liver, and rabbit liver, 
using a modification of the method of K.V. Rajagopalan, I. Fridovich, and P. Handler, J. 
Biol. Chem., 237 (1962) 922-928.   
 Rabbit livers were purchased from Pel-Freez Biologicals of Rogers, Arkansas.  
Golden Forest® brand beef livers and beef kidneys were purchased from Food Lion LLC 
of Salisbury, North Carolina.   Rumba® brand beef livers and beef kidneys were 
purchased from Wal-Mart Stores Inc. of Bentonville, Arkansas.  If frozen, the tissue 
samples were thawed in a 0.05 M potassium phosphate buffer solution containing 0.1 
mM EDTA and had a pH of 6.8. 
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 The tissue samples were homogenized using a Waring® laboratory blender for 3 
minutes in a 1:5 mixture of tissue sample and 0.05 M potassium phosphate buffer which 
contained 0.1 mM EDTA, pH of 6.8.  The mixture was then rapidly warmed to a 
temperature of 50
o
C in a preheated 75
o
C water bath and the temperature of the solution 
was maintained between 50
o
C and 55
o
C for ten minutes.  The mixture was then placed in 
an ice-bath and allowed to cool to between 10
o
C and 15
o
C with frequent stirring.  The 
mixture was then centrifuged for 30 minutes at 4000 rpm and 4
o
C in a refrigerated type 
IEC Centra-8R centrifuge manufactured by International Equipment Company.  The 
supernatant obtained was filtered through glass wool into a graduated cylinder in order to 
directly determine the volume of supernatant collected.  The supernatant was then 
transferred to a suitable Erlenmeyer flask and placed in an ice-bath.  While stirring in the 
ice-cold water bath, ammonium sulfate was added during a time-duration of five minutes 
in the amount of 313 grams (NH4)2SO4 per liter of original supernatant collected.  The 
solution was allowed to equilibrate for 45 minutes longer while stirring in the ice-bath 
and then centrifuged for 10 minutes at 4
o
C and 4000 rpm.  The supernatant collected was 
discarded and the precipitate was dissolved in 0.05 M potassium phosphate buffer which 
contained 0.1 mM EDTA, pH of 7.8 at an amount of (80 milliliters buffer per liter of 
original supernatant).  All solutions from the centrifuge tubes were then collected and 
transferred to a single vessel in which the pH was adjusted to 7.8 with concentrated 
sodium hydroxide solutions using a Fisher Scientific Accumet® Model 10 pH meter.  
The resulting solution was then re-centrifuged to remove any protein that precipitated 
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during the latter stages of the purification procedure or pH adjustment.  The purification 
was stopped here, at the ammonium sulfate fractionation, and the solution was stored in 
small plastic vials which were stored in a freezer at -20
o
C for future enzymatic assay 
tests.   
 
 Lowry Protein Assay 
 Protein concentrations of the partially purified enzyme samples were determined 
spectrophotometrically according to the often-cited general use protein assay first 
described in 1951 by Lowry et al., J. Biol. Chem., (1951) 265-275.  This Lowry Protein 
Assay (LPA) utilizes albumin from bovine serum as the primary standard.  This protein 
standard was purchased from the Sigma Chemical Company.  Five concentrations of the 
standard were prepared in triplicate and their absorbances measured at 750 nm on a Cary 
100 Bio UV-Vis Spectrophotometer.  A calibration curve was then constructed using the 
fifteen data points.  Two dilutions of the sample enzyme solutions were prepared in 
triplicate.  These solutions were treated in like manner to the standard solutions and their 
absorbances also read at 750 nm.  Calculations were performed using the calibration 
curve to determine the protein concentrations in the dilute sample solutions.  These 
values were then used to determine protein concentrations in the original enzyme 
solutions and the values averaged.  This average value was then used to calculate the 
volume of enzyme solution needed for the desired final protein concentration in the 
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cuvettes during enzyme assays.   In most cases, a 1 mg/mL final protein concentration 
was used for this research.   
 
 Enzyme Assays 
 All assays were determined by measuring the absorbances of a mixture that 
contained the enzyme and substrate in a solution that contained 33 mM potassium 
phosphate buffer and 0.07 mM ethylenediaminetetraacetic acid (EDTA) and had a pH of 
7.8.   All concentrations noted in this research paper are the final concentrations that are 
present in the cuvette.  Refer to Table 1 for the concentrations and parameters used in the 
assays.  An upward arrow (↑) or downward arrow (↓) in front of a wavelength value 
within the experimental conditions table signifies whether there was an increase or 
decrease in the absorbance being measured for that particular assay.  In order to produce 
positive absorbance changes, the sample cuvettes and blank cuvettes were switched in the 
holders where a decrease in absorbance occurred.  All spectrophotometric assays were 
run in the presence of a reference cuvette that contained all ingredients except the 
substrate.  The ingredients in the cuvettes consisted of 2000 µL of 0.05 M potassium 
phosphate buffer - 0.1 mM EDTA – pH 7.8, 100 µL of 0.03 M potassium ferricyanide 
solution if using the ferricyanide method, appropriate enzyme preparation solution to give 
a 1mg/ml final protein concentration (normally about 200 µL), appropriate amount of 
substrate solution to give the desired final substrate concentration as shown in Table 1 
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(normally about 100 µL), and sufficient de-ionized water to give a final assay volume of 
3000 µL.  In the reference cuvette, the substrate solution was replaced by the solvent used 
to dissolve the substrate.  Phenazine methosulfate, benzaldehyde, and N
1
-
methylynicotinamide substrates used de-ionized water as a solvent.  Methotrexate used 
0.01 M NaOH, xanthine used 0.02 M NaOH, and phenanthridine used acetone as 
solvents.  The raw data obtained from the initial rate continuous assay method is in terms 
of absorbance change per minute.  This allows calculation of the specific activity of the 
enzyme.  The procedural steps for this assay are as follows:  all prescribed ingredients 
except for the substrate solution were transferred to the blank and sample cuvettes.  The 
cuvettes were then placed in the UV-Vis spectrophotometer cell holder which had been 
adjusted to a temperature of 37.0
o
C.  The solutions were allowed to incubate for 5 
minutes.  At that point, the prescribed volume of substrate solution was transferred to the 
sample cuvette and the cuvette was inverted 3 to 4 times to mix which was then 
immediately placed back in the instrument holder.  The instrument was programmed to 
monitor the enzyme-substrate reaction for two minutes at the wavelength specific for the 
oxidized product.  In the case of the enzyme assays that used the artificial electron 
acceptor, potassium ferricyanide, the instrument monitored the coupled reduction of 
ferricyanide [Fe
+3
(CN)6] to ferrocyanide [Fe
+2
(CN)6] at a wavelength of 420 nm.  After 
the data had been collected, the absorbance change per minute was calculated by the Cary 
Win UV software.  The raw data so obtained was then be used to calculate the specific 
activity of the enzymes.   
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 In contrast to the initial rate continuous assay method where the UV solution 
ingredients were mixed in the cuvette, the discontinuous assay (long-term incubation) 
solution ingredients are transferred to and mixed in a 25 mL Erlenmeyer flask.  See Table 
1 for the concentrations and parameters used in the assays.  The procedural steps were as 
follows:  all ingredients minus the substrate are placed in the 25 mL Erlenmeyer flasks.  
The same principle applies for ingredient volumes for the long-term incubation 
discontinuous assays as did for the two-minute initial rate continuous assays discussed 
earlier.   A blank solution was also prepared.  The 25 mL flasks were then placed in a 
Fisher Shaking Water Bath Model 127® where the bath temperature had been adjusted to 
37.0
o
C.  While gently shaking, the solutions were allowed to stay in the shaker bath for 5 
minutes to assure that they are at the temperature of the bath (37
o
C).  At this point, the 
prescribed volume of substrate solution is added to the sample solution flask.  The 
solutions are then allowed to incubate while gently shaking for exactly 30 minutes at 
37
o
C.   The reaction is then stopped by adding 1.0 mL of ice-cold 95% ethanol to the 
reaction mixtures.  This should also precipitate out the protein.  The contents of the flask 
are then immediately transferred to test tubes which are placed on ice and allowed to cool 
for 15 minutes.  The tubes are then centrifuged in an IEC Clinical Centrifuge for 10 
minutes to spin down the protein and to clarify the solution for UV-Vis analysis.  The 
solutions were then transferred to a cuvette and placed in the holder.  The wavelength 
specific for the oxidative product was entered into the software and the absorbances were 
read at a temperature of 25
o
C.  For the case of potassium ferricyanide assays, the 
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wavelength was set at 420 nm.  The blank solution was placed in the appropriate holder 
to subtract out the absorbance of this solution that did not contain substrate.   
  The two minute initial rate continuous assay method was used to evaluate the 
menadione inhibition of phenazine methosulfate oxidation by rabbit liver and bovine 
kidney aldehyde oxidase.  The prescribed amount of inhibitor solution was added to both 
the sample and blank solution and the absorbance change per minute was obtained as 
described earlier for the two-minute continuous assays.  Two concentrations of 
menadione, 3.2 x 10
-5
 M and 9.1 x 10
-5
 M, were evaluated for their effect on the 
oxidation reactions for the two enzymes.  The results are discussed in the Results section.   
 The initial rate two-minute continuous assay method was also used to evaluate the 
inhibition of 0.3 M methanol on phenazine methosulfate oxidation by bovine kidney, 
bovine liver and rabbit liver aldehyde oxidase.  The prescribed amount of methanol was 
added to both the blank and sample solutions contained in the 1cm UV cuvettes.   The 
absorbance change per minute was obtained as described earlier for the menadione assay.   
The results are discussed in the Results section.   
 A scanning experiment was performed on the phenazine methosulfate oxidation 
reaction by bovine kidney aldehyde oxidase and rabbit liver aldehyde oxidase.  This 
scanning experiment was performed in order to help verify that the oxidative product of 
phenazine methosulfate was truly the cause of the increase in absorbance at 520 nm due 
to the fact that phenazine methosulfate is known to be involved in non-enzymatic 
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oxidation.  The solutions were scanned every five minutes for 55 minutes (12 total scans) 
from 350 nm to 600 nm.  Within this range, the peak arising from phenazine methosulfate 
as well as the peak arising from its red oxidized product can be observed.  Phenazine 
methosulfate has a maximum absorbance at about 380 nm while its red oxidized product 
has a maximum absorbance at 520 nm.  Initially, the PMS concentration used for the 
scans was the same as used for the specific activity assays, which was 0.2 mM.  
However, this concentration produced a very large PMS peak with an absorbance of 
about 3.2.  The concentration was reduced to 0.1 mM but still produced a high 
absorbance of about 2.5.  The concentration was then reduced five-fold to 0.04 mM.  This 
produced a reasonable absorbance value between 1.0 and 1.2 for the PMS peak.  After the 
best concentration was determined to produce a reasonable level of absorbance, the 
procedure was carried out the same as the two-minute assay procedure with respect to 
solution ingredients, except for the difference in substrate concentration just discussed. 
 Evaluation of the purification procedure was accomplished by use of the 30 
minute discontinuous assay method as described earlier.  This evaluation utilized the 
PMS oxidation reaction and the xanthine oxidation reaction, both by the bovine kidney 
enzyme. 
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Table 1.  Experimental Conditions for Enzyme Assays.  Concentrations are what are 
present in 3 mL of enzyme solution.  Up/down arrows indicate an increase or decrease in 
absorbance being measured.  Same conditions used for 2 minute continuous assays and 
30 minute discontinuous assays unless otherwise indicated.  
Substrate Name 
Substrate 
Conc. 
Wavelength (λ) 
(Increase or 
Decrease) 
Molar 
Absorptivity 
(M
-1
cm
-1
) 
Potassium 
Ferricyanide 
Conc. 
Phenazine 
Methosulfate 
0.2 mM ↑ 520 nm 11,700 N/A 
N’-
Methylnicotinamide 
1.0 mM ↓ 420 nm 1,020 1.0 mM 
Benzaldehyde 0.05 mM ↓ 249 nm 17,540 N/A 
Methotrexate 0.167 mM ↓ 420 nm 1,020 1.0 mM 
Methotrexate 0.333 mM ↓ 420 nm 1,020 1.0 mM 
Phenanthridine 1.0 mM ↑ 322 nm 9,000 N/A 
Xanthine (2’Assay) 0.03 mM ↑ 295 nm 9,500 N/A 
Xanthine (30’Assay) 0.17mM ↓ 420 nm 1,020 1.0mM 
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CHAPTER IV 
RESULTS 
Bovine Kidney Enzyme Specific Activities 
 The specific activity of the bovine kidney enzyme as determined by the two- 
minute initial rate continuous assay method showed a large amount of xanthine oxidase 
activity (0.0327 µmols/min/mg) relative to the aldehyde oxidase activities measured.  The 
highest aldehyde oxidase activity measured was from the N
1
-methylnicotinamide  
substrate (an endogenous substrate for AO) and this activity was only 38% of the 
xanthine oxidase activity found using the xanthine substrate (the primary endogenous 
substrate for XO).  The order of activity for the aldehyde oxidase substrates from highest 
to lowest is N
1
-methylnicotinamide with 0.0124 µmols/min/mg followed by phenazine 
methosulfate at 0.0052 µmols/min/mg and finally benzaldehyde at 0.0027 µmols/min/mg.  
There was no detectable activity observed for the aldehyde oxidase substrates, 
methotrexate and phenanthridine for the bovine kidney enzyme (Fig. 31, Table 2).  
However, our research shows that bovine kidney aldehyde oxidase catalyzed the 
oxidation of the endogenous substrate N
1
-methylynicotinamide and the xenobiotic 
benzaldehyde as well as the well-known aldehyde oxidase substrate phenazine 
methosulfate.
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Figure 31.  Beef Kidney Enzyme Specific Activities.  Substrate comparisons as 
determined by the two-minute initial rate continuous enzyme assays of the bovine kidney 
enzyme.   
 
Substrate µmols/min/mg 
Xanthine 0.0327 +/- 0.0060 (N=3) 
N’-Methylnicotinamide 0.0124 +/- 0.0029 (N=2) 
Phenazine Methosulfate 0.0052 +/- 0.0017 (N=5) 
Benzaldehyde 0.0027 +/- 0.0005 (N=3) 
Methotrexate None Detected (N=2) 
Phenanthridine None Detected (N=2) 
             
Table 2.  Activity Values for Beef Kidney (Corresponding to Fig. 31).  +/- Values are 
standard deviations.  N is number of sample preparations. 
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Bovine Liver Enzyme Specific Activities 
 Like that of the bovine kidney enzyme, the specific activity of the bovine liver 
enzyme as determined by the two-minute initial rate continuous assay method showed a 
higher activity for xanthine oxidase than for aldehyde oxidase.  The highest aldehyde 
oxidase activity measured was from the oxidation of the N
1
-Methylnicotinamide substrate 
and this activity was only 76% of the xanthine oxidase activity found using the xanthine 
substrate.  The order of activity for the five aldehyde oxidase substrates from highest to 
lowest is N
1
-Methylnicotinamide at 0.0600 µmols/min/mg followed by benzaldehyde at 
0.0384 µmols/min/mg, phenazine methosulfate at 0.0363 µmols/min/mg, phenanthridine 
at 0.0262 µmols/min/mg and lastly methotrexate at 0.0234 µmols/min/mg.  Xanthine 
oxidase specific activity for the bovine liver enzyme was measured to be 0.0793 
µmols/min/mg (Fig. 32, Table 3).  Our research showed that bovine liver aldehyde 
oxidase catalyzed the oxidation of all aldehyde oxidase substates evaluated.  
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Figure 32.  Beef Liver Enzyme Specific Activities.  Substrate comparisons as determined 
by the two-minute continuous initial rate enzyme assays of the bovine liver enzyme.   
 
Substrate µmols/min/mg 
Xanthine 0.0793 +/- 0.0063 (N=3) 
N’-Methylnicotinamide 0.0600 +/- 0.0039 (N=3) 
Benzaldehyde 0.0384 +/- 0.0026 (N=3) 
Phenazine Methosulfate 0.0363 +/- 0.0033 (N=3) 
Phenanthridine 0.0262 +/- 0.0028 (N=3) 
Methotrexate 0.0234 +/- 0.0002 (N=2) 
 
Table 3.  Activity Values for Beef Liver (Corresponding to Fig. 32).  +/- Values are 
standard deviations.  N is number of sample preparations. 
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Rabbit Liver Enzyme Specific Activities 
 Unlike that of the bovine kidney and bovine liver enzymes, the rabbit liver 
enzyme as determined by the two-minute initial rate continuous assay method showed a 
lower xanthine oxidase activity than aldehyde oxidase activity.  The xanthine oxidase 
activity was 50% lower than the lowest aldehyde oxidase activity measured and 87% 
lower than the highest aldehyde oxidase activity measured.  The order of activity for the 
five aldehyde oxidase substrates evaluated from highest to lowest is N
1
-
Methylnicotinamide at 0.8243 µmols/min/mg followed by methotrexate at 0.5385 
µmols/min/mg, phenazine methosulfate at 0.3658 µmols/min/mg, phenanthridine at 
0.3649 µmols/min/mg, and lastly benzaldehyde at 0.2069 µmols/min/mg.  The specific 
activity for xanthine oxidase was measured to be 0.1033 µmols/min/mg (Fig. 33, Table 
4).  Our research showed that rabbit liver aldehyde oxidase significantly catalyzed the 
oxidation of all five aldehyde oxidase substrates evaluated. 
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Figure 33.   Rabbit Liver Enzyme Specific Activities.  Substrate comparisons as 
determined by the two-minute initial rate continuous enzyme assays of the rabbit liver 
enzyme.   
 
Substrate µmols/min/mg 
N’-Methylnicotinamide 0.8243 +/- 0.1515 (N=3) 
Methotrexate 0.5385 +/- 0.0657 (N=3) 
Phenazine Methosulfate 0.3658 +/- 0.0580 (N=6) 
Phenanthridine 0.3649 +/- 0.0542 (N=3) 
Benzaldehyde 0.2069 +/- 0.0171 (N=3) 
Xanthine 0.1033 +/- 0.0139 (N=3) 
 
Table 4.  Activity Values for Rabbit Liver (Corresponding to Fig. 33).  +/- Values are 
standard deviations.  N is number of sample preparations. 
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Bovine Kidney 30’ Discontinuous Enzyme Assays                                                                    
Long-Term (Time-Course) Incubation Method 
 Due to very low activities found for bovine kidney aldehyde oxidase following 
the two-minute initial rate continuous assay method, discontinuous thirty-minute 
incubation assays were used to evaluate the activity of the enzyme using aldehyde 
oxidase substrates phenanthridine, N
1
-methylnicotinamide, and phenazine methosulfate 
(PMS).  The activity of bovine kidney xanthine oxidase was also evaluated using 
xanthine as the sole substrate.   As previously discussed, the discontinuous long-term 
incubation assays allow for the calculation of the amount of oxidative product formed in 
terms of molarity or micromoles of product produced.  For this research project, the 
amount shown is in micromoles of oxidized product formed in 3 mLs of solution since 
this is the total cuvette volume used in the two-minute initial rate continuous assays.  For 
the aldehyde oxidase substrates, phenanthridine produced the largest amount of product 
at 0.3108 µmols/3 ml followed by N
1
-methylnicotinamide at 0.0755 µmols/3ml and 
finally phenazine methosulfate at 0.0348 µmols/3ml.  The amount of product produced 
by the xanthine oxidase-xanthine substrate complex was 0.1534 µmols/3ml which falls 
between that of phenanthridine and N
1
-methylnicotinamide substrates (Fig. 34, Table 5). 
There was approximately one order of magnitude difference between the highest amount 
of product produced (oxidized phenanthridine) to the smallest amount of product 
produced (oxidized PMS). 
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Figure 34.  Beef Kidney Discontinuous Enzyme Assays 30’ Incubation.  Substrate 
comparisons as determined by the thirty-minute discontinuous long-term incubation 
enzyme assays of the bovine kidney enzyme.   
 
 
      Substrate Results 
Phenanthridine 0.3108 +/- 0.0271 (N=3) 
Xanthine 0.1534 +/- 0.0309 (N=6) 
N’-Methylnicotinamide 0.0755 +/- 0.0120 (N=4) 
Phenazine Methosulfate 0.0348 +/- 0.0064 (N=13) 
 
Table 5.  Beef Kidney Assay Values (Corresponding to Fig. 34).   +/- Values are standard 
deviations.  N is number of sample preparations. 
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Repetitive Scans of the Phenazine Methosulfate  
Oxidation Reaction by Aldehyde Oxidase 
 The benefit of doing repetitive scans of the phenazine methosulfate oxidation 
reaction over the wavelength from 350 nm to 600 nm is the ability to observe the 
decrease in absorbance of the substrate and the increase in absorbance of the oxidized 
product.  If a decrease in the absorbance of the substrate is observed concurrently with an 
increase in absorbance of oxidized product this provides good evidence that the actual 
oxidation reaction is taking place.  The substrate in this case is phenazine methosulfate 
and the oxidized product is 10-methylphenazine-2(10H)-one which is a red product that 
has a maximum absorbance at about 520 nm.  A repetitive scanning experiment was 
performed on a blank solution to determine if any non-enzymatic reactions were taking 
place during the 55 minute run that would cause a rise in absorbance at 520 nm (Fig. 36).  
The blank cuvette did not contain any enzyme solution.  Three other repetitive scanning 
experiments were performed which included phenazine methosulfate oxidation by bovine 
kidney aldehyde oxidase at two different concentrations of enzyme (1 mg/mL and 4 
mg/mL) (Fig. 37 and Fig. 38) and by rabbit liver aldehyde oxidase at 1 mg/ml protein 
concentration (Fig. 35).  The results of the repetitive scanning experiments are as follows:  
A slight rise at 520 nm was seen in the blank repetitive spectrum.  The difference in the 
initial scan absorbance (0 minutes) at 520 nm and the final scan absorbance (55 minutes) 
at 520 nm for the blank solution was equal to 0.0321.  The difference in initial scan 
absorbance (0 minutes) at 520 nm and final scan absorbance (55 minutes) at 520 nm for 
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the 1 mg/mL bovine kidney enzyme was 0.0750 and the difference for the 4 mg/mL 
bovine kidney enzyme was 0.0902.  A much larger difference of 0.4942 was seen in the 1 
mg/mL rabbit liver enzyme.  For all repetitive scanning experiments performed, a 
correlation between the drop in absorbance of the phenazine methosulfate substrate peak 
to the oxidized phenazine methosulfate peak was observed.  The bovine kidney enzyme 
repetitive spectrums indicate that there is a definite rise in absorbance at 520 nm thus 
revealing the production of oxidized PMS.  At the 4 mg/mL bovine kidney enzyme 
concentration the scans begin to take on a similar appearance to that of the rabbit liver 
enzyme.   As mentioned earlier, the blank spectrum also shows an increase in absorbance 
at 520 nm.  Regarding this as some form of non-enzymatic oxidation it would make sense 
to subtract that value from the results of the enzyme preparations.  Being that the case, a 
positive value is still obtained for all three enzyme preparations indicating that the 
oxidation of phenazine methosulfate by aldehyde oxidase has occurred.  It is important to 
point out though, that the spectrums for rabbit liver and bovine kidney are not identical.  
When comparing the rabbit liver spectrum (Fig. 35) to the 4 mg/mL bovine kidney 
spectrum (Fig. 38) the isosbestic points differ.  This could indicate that different chemical 
species and therefore different oxidation products are forming by the rabbit liver enzyme 
and the bovine kidney enzyme.    
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Figure 35.  Repetitive Scanning Spectrum of the Oxidation of PMS by Rabbit Liver 
Aldehyde Oxidase.  1 mg/ml enzyme concentration and 0.04 mM PMS concentration.  
Scans ran at 0 minutes and every 5 minutes thereafter up to 55 minutes (12 scans total). 
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Figure 36.  Repetitive Scanning Spectrum of 0.04 mM PMS Solution. 0 mg/mL of 
enzyme solution.  Scans ran at 0 minutes and every 5 minutes thereafter up to 55 minutes 
(12 scans total).   
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Figure 37.  Repetitive Scanning Spectrum of the Oxidation of PMS by Bovine Kidney 
Aldehyde Oxidase (1 mg/mL).  1 mg/ml enzyme concentration and 0.04 mM PMS 
concentration.  Scans ran at 0 minutes and every 5 minutes thereafter up to 55 minutes 
(12 scans total). 
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Figure 38.  Repetitive Scanning Spectrum of the Oxidation of PMS by Bovine Kidney 
Aldehyde Oxidase (4 mg/mL).  4 mg/ml enzyme concentration and 0.04 mM PMS 
concentration.  Scans ran at 0 minutes and every 5 minutes thereafter up to 55 minutes 
(12 scans total). 
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Inhibition of Phenazine Methosulfate Oxidation by Menadione and Methanol 
 The inhibition of the oxidation reaction of phenazine methosulfate by rabbit liver 
and bovine kidney aldehyde oxidase as determined by the two-minute initial rate 
continuous assay method showed two very different results when studying the well 
known menadione inhibitor against the two different enzymes.  At a menadione 
concentration of 3.2 x 10
-5
 M the oxidation reaction catalyzed by the rabbit liver enzyme 
was inhibited by 36.3%.  Increasing the concentration of menadione to 9.1 x 10
-5 
M, a 3-
fold increase, the oxidation of phenazine methosulfate by rabbit liver aldehyde oxidase 
was inhibited by 53.6% (Fig. 39).   On the contrary, the oxidation of phenazine 
methosulfate by bovine kidney aldehyde oxidase showed no inhibition at either of the 
concentrations of menadione used in the rabbit liver experiments.  It is important to note 
however, that the activity as measured by the phenazine methosulfate oxidation reaction 
by bovine kidney aldehyde oxidase was at low levels and the inhibition studies were 
performed and calculated on these values.   
 The inhibition of the oxidation reaction of phenazine methosulfate by rabbit liver, 
bovine liver, and bovine kidney AO as determined by the two-minute initial rate 
continuous assay method showed similar results for the bovine tissues but a different 
result for the rabbit liver tissue when comparing them to methanol inhibition (Fig. 40, 
Table 6).  At a methanol concentration of 0.3M, both bovine aldehyde oxidases were 
inhibited by 30%.  Rabbit liver AO, however was only inhibited by 6%.   
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Figure 39.  Menadione Inhibition of PMS Oxidation by Aldehyde Oxidase.  Inhibition of 
rabbit liver and bovine kidney aldehyde oxidase by 3.2x10
-5
M and 9.1x10
-5
M menadione.  
Determined on the oxidation of phenazine methosulfate reaction by the two-minute initial 
rate continuous enzyme assay. 
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Figure 40.  0.3M MeOH Inhibition on AO-PMS Oxidation.  Inhibition of bovine kidney, 
bovine liver, and rabbit liver aldehyde oxidase by 0.3M methanol.  Determined on the 
oxidation of phenazine methosulfate reaction by the two-minute initial rate continuous 
enzyme assay.  Bars on the right are with 0.3M methanol.  Bars on the left are without the 
methanol inhibitor. 
 
 
 
Species/Tissue % Inhibited by 0.3M 
MeOH 
Beef Liver 29.75 
Beef Kidney 30.00 
Rabbit Liver 6.15 
 
Table 6.  Percent Inhibition by Methanol of AO-PMS (Corresponding to Fig. 40) 
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Evaluation of the Enzyme Purification Procedure 
 The primary purpose of performing the following experiments was to verify that 
the purification procedure was producing expected and typical results though at the same 
time valuable enzymatic activity data was obtained.   Expected and typical results for an 
enzyme purification procedure are an increase in enzyme activity measurements as the 
steps in the purification procedure progress.  Our experiments show this to be the case as 
described below.   
 Recalling from the enzyme purification procedure previously discussed; the 
procedure begins by homogenizing the tissue in 0.05 M potassium phosphate buffer,  heat 
treating the homogenized solution between 50-55
o
C, and obtaining  a supernatant by 
centrifuging at 4000 rpm. The supernatant was then reacted with ammonium sulfate at 
313 g/L of original supernatant, and the precipitate obtained and collected by centrifuging 
at 4000 rpm.  The precipitate was then dissolved in 0.05 M potassium sulfate buffer at 80 
mL/L of original supernatant, and the solution adjusted to a pH of 7.8.  The solution was 
re-centrifuged to remove any additional precipitated protein. Using the 30 minute long 
term incubation assay method to measure the production of uric acid catalyzed by 
xanthine oxidase, three different points of the purification procedure were evaluated.  The 
results were as expected, with an increase in the micromoles of uric acid produced as the 
steps in the purification procedure progressed.   There was a 2.2-fold increase (120.1%) 
in micromoles of uric acid formed when testing the supernatant obtained after the ten-
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minute 50-55
o
C heat treatment over the crude homogenate.   There was a 4.7-fold 
increase (368.2%) in uric acid formation when testing the ammonium sulfate fraction, 
which is the final step carried out for this research project, compared to the crude 
homogenate from the Waring Laboratory blender (Fig. 41, Table 7). 
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Figure 41.  Beef Kidney XO-Xanthine Oxidation 30’ Incubation Assay.  30-minute 
discontinuous, long-term incubation enzyme assays for purpose of evaluating the 
purification procedure.  Results are determined on the xanthine oxidation reaction by 
bovine kidney xanthine oxidase.  1 mg/mL protein concentrations for each step. 
 
Purification Point Results 
Crude Homogenate from Blender 0.0274 +/- 0.0042 (N=3) 
 
Supernatant Following Heat 
Treatment 
0.0603 +/- 0.0134 (N=3) 
Ammonium Sulfate Fraction 0.1283 +/- 0.0160 (N=3) 
 
Table 7.  Beef Kidney XO Assay Results (Corresponding to Fig. 41).  +/- Values are 
standard deviations.  N is number of sample preparations. 
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 An additional 30 minute long term incubation assay evaluation was performed on 
the supernatant following heat treatment and the ammonium sulfate fraction by 
measuring the micromoles formed of oxidized phenazine methosulfate catalyzed by 
aldehyde oxidase.  There was a 1.3-fold increase (26.9%) in micromoles of oxidized 
phenazine methsulfate formed when testing the ammonium sulfate fraction over the 
supernatant following heat treatment (Fig. 42, Table 8).  Both experiments described 
above show an increase in product formation when testing the latter step of the enzyme 
purification as the procedure progresses.  This is the expected outcome of such an 
experiment.   
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Figure 42.  Beef Kidney AO-PMS Oxidation 30’ Incubation Assay.  30-minute 
discontinuous, long-term incubation enzyme assays for purpose of evaluating purification 
procedure.  Determined on the oxidation of phenazine methosulfate reaction by bovine 
kidney aldehyde oxidase.  1 mg/mL protein concentration for each step. 
 
Purification Point Results 
Supernatant Following Heat 
Treatment 
0.0271 +/- 0.0005 (N=3) 
Ammonium Sulfate Fraction 0.0344 +/- 0.0020 (N=3) 
 
Table 8.  Beef Kidney AO Assay Results (Corresponding to Fig. 42).  +/- Values are 
standard deviations.  N is number of sample preparations.
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CHAPTER V 
DISCUSSION 
 Results from our research have agreed with previous work by other scientists that 
the enzyme aldehyde oxidase does exist within the bovine kidney tissue and contributes 
to the metabolism of xenobiotics as shown by our limited number of substrate oxidation 
experiments, repetitive scanning experiments, and inhibition studies on the partially 
purified enzyme.  When comparing the bovine kidney aldehyde oxidase activity to that of 
bovine liver and rabbit liver the results are approximately one order of magnitude and 
two orders of magnitude lower, respectively.  Of the three tissues evaluated, rabbit liver 
showed the highest aldehyde oxidase activity for all five AO substrate oxidations 
followed by bovine liver and then bovine kidney, as the following figures and tables 
illustrate (Figs. 43-47, Tables 9-13).
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Figure 43.  Phenanthridine-Enzyme Activity.  Tissue comparisons for the oxidation of 
phenanthridine by aldehyde oxidase as determined by the 2-minute initial rate continuous 
enzyme assay. 
 
 
 
 
Species/Tissue µmols/min/mg 
Rabbit Liver  0.3649 +/- 0.0542 (N=3) 
Beef Liver 0.0262 +/- 0.0028 (N=3) 
Beef Kidney None Detected (N=2) 
 
 
Table 9.  Assay Results for Phenanthridine (Corresponding to Fig. 43).  +/- Values are 
standard deviations.  N is number of sample preparations. 
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Figure 44.  Benzaldehyde-Enzyme Activity.  Tissue comparisons for the oxidation of 
benzaldehyde by aldehyde oxidase as determined by the 2-minute initial rate continuous 
enzyme assay. 
 
 
 
       
Species/Tissue µmols/min/mg 
Rabbit Liver  0.2069 +/- 0.0171 (N=3) 
Beef Liver 0.0384 +/- 0.0026 (N=3) 
Beef Kidney 0.0027 +/- 0.0005 (N=3) 
 
 
Table 10. Assay Results for Benzaldehyde (Corresponding to Fig. 44).  +/- Values are 
standard deviations.  N is number of sample preparations. 
 
 
 
 
85 
 
 
 
 
Figure 45.  Methotrexate-Enzyme Activity.  Tissue comparisons for the oxidation of 
methotrexate by aldehyde oxidase as determined by the two-minute initial rate 
continuous enzyme assay. 
 
 
 
 
     Species/Tissue µmols/min/mg 
Rabbit Liver  0.5385 +/- 0.0657 (N=3) 
Beef Liver 0.0234 +/- 0.0002 (N=2) 
Beef Kidney None Detected (N=2) 
 
 
Table 11.  Assay Results for Methotrexate (Corresponding to Fig. 45).  +/- Values are 
standard deviations.  N is number of sample preparations. 
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Figure 46.  PMS-Enzyme Activity.  Tissue comparisons for the oxidation of phenazine 
methosulfate by aldehyde oxidase as determined by the 2-minute initial rate continuous 
enzyme assay. 
 
 
 
 
       Species/Tissue µmols/min/mg 
Rabbit Liver  0.3658 +/- 0.0580 (N=6) 
Beef Liver 0.0363 +/- 0.0033 (N=3) 
Beef Kidney 0.0052 +/- 0.0017 (N=5) 
 
 
Table 12.  Assay Results for Phenazine Methosulfate (Corresponding to Fig. 46).   
+/- Values are standard deviations.  N is number of sample preparations. 
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Figure 47.  NMN-AO Activity.  Tissue comparisons for the oxidation of N
1
-
Methylnicotinamide by aldehyde oxidase as determined by the two-minute initial rate 
continuous enzyme assay. 
 
 
 
 
         Species/Tissue µmols/min/mg 
Rabbit Liver  0.8243 +/- 0.1515 (N=3) 
Beef Liver 0.0600 +/- 0.0039 (N=3) 
Beef Kidney 0.0124 +/- 0.0029 (N=2) 
 
 
Table 13.  Assay Results for NMN (Corresponding to Fig. 47).  +/- Values are standard 
deviations.  N is number of sample preparations. 
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 This rank order of activities for the tissues are what was expected due to the fact 
that the liver is the main organ responsible for metabolic reactions and that the rabbit 
liver enzyme has shown to be one of the more potent sources of AO for many years and 
is often used as a standard.  Of the five AO substrates evaluated, the endogenous 
compound N
1
-methylnicotinamide produced the highest activity results for all three 
tissues.  The values for this endogenous substrate were higher than any of the xenobiotic 
substrates evaluated.  The research also indicates that the levels of AO activity found in 
the tissues are dependent upon the substrate used.  In a study by A. David Rodrigues (53) 
on the human liver aldehyde oxidase enzyme, it was also determined that the charged 
substrate, NMN, produced a much higher aldehyde oxidase activity than did uncharged 
substrates like benzaldehyde or 6-methylpurine.  Our study also showed that the aldehyde 
oxidase activity was higher for the charged compound N
1
-methylnicotinamide than for 
the uncharged compound benzladehyde for all three tissues evaluated.  The reason for 
this substrate variability could be in the existence of and levels of isoenzymes.  
Isoenzymes often display different kinetic properties and therefore can have different 
affinities for different substrates.  Isoenzymes have been discovered in rodents such as 
mice but not in humans. Two separate isoenzymes for mouse aldehyde oxidase have been 
identified as AOX1 and AOH1 (54).  Currently, only a single isoenzymatic form of 
aldehyde oxidase has been detected for the human liver enzyme (54) though more 
research is necessary to confirm the lack of other forms.  For this project, no research was 
conducted to indicate either the lack of or existence of isoenzymes for the bovine tissues.   
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 As with many experimental research projects, unusual, unexpected, and aberrant 
results can be produced.  Such is the case when comparing the thirty-minute long term 
incubation enzyme assay results to the two-minute initial rate continuous assay results for 
the oxidation of phenanthridine by bovine kidney aldehyde oxidase.  The activity rank 
order for the 30 minute discontinuous assay for the following substrates is phenanthridine 
> xanthine > NMN > PMS.  The activity rank order for the 2 minute continuous assay for 
the same substrates is xanthine > NMN > PMS > phenanthridine (not detectable).  The 
phenanthridine substrate showed the highest oxidase activity for the 30 minute long term 
incubation assay but was not detected by the 2 minute initial rate assay.  Was there some 
form of non-enzymatic oxidation taking place during the 30 minute incubation that was 
not seen in the 2 minute assay?  An explanation for these unexpected aberrant results is 
unknown at this time.  Further research is warranted to confirm the product produced in 
the 30 minute incubation assay method is valid.  
 Our research also showed that there is a significant amount of xanthine oxidase 
activity within the two bovine tissues.  As a matter of fact, xanthine oxidase activity 
exceeded aldehyde oxidase activity for the bovine kidney and the bovine liver tissues.  
The reverse was seen in the rabbit liver tissue.  Though the rank order of activities from 
highest to lowest for the tissues remained the same for xanthine oxidase activity (rabbit 
liver followed by bovine liver and then bovine kidney), the results were much closer as 
compared to the aldehyde oxidase values as the following figure and table shows (Fig. 
48, Table 14).  
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Figure 48.  Xanthine-XO Activity.  Tissue comparisons for the oxidation of xanthine by 
xanthine oxidase as determined by the 2-minute initial rate continuous enzyme assay. The 
bars are much closer is size than those of the aldehyde oxidase charts. 
 
 
Species/Tissue µmols/min/mg 
Rabbit Liver  0.1033 +/- 0.0139 (N=3) 
Beef Liver 0.0793 +/- 0.0063 (N=3) 
Beef Kidney 0.0327 +/- 0.0060 (N=3) 
 
Table 14. Assay Results for Xanthine (Corresponding to Fig. 48).  +/- Values are 
standard deviations.  N is number of sample preparations. 
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 Instead of one and two orders of magnitude higher, rabbit liver xanthine oxidase 
activity was only 1.3 and 3.2 times greater than bovine liver and bovine kidney 
respectively.  In terms of the ratio of xanthine oxidase activity over aldehyde oxidase 
activity, bovine kidney is at 8.0, bovine liver is at 2.1 and rabbit liver is at 0.2. 
 It is important to note that the purification procedure utilized for the partial 
purifications was the same for aldehyde oxidase and xanthine oxidase.  This could be 
resulting in co-purification of these two enzymes.  It may not be known in all cases how 
much contribution each enzyme has for catalyzing these oxidation reactions.  However, it 
is known that xanthine is not oxidized by aldehyde oxidase and that NMN is not oxidized 
by xanthine oxidase.  Benzaldehyde, on the other hand, is not known to only be oxidized 
by either one of the partially purified enzymes, though it is more commonly used as an 
aldehyde oxidase substrate.  In this case, one or both of the enzymes may have 
contributed to oxidation of benzaldehyde.   
 Methotrexate, the aldehyde oxidase substrate of clinical significance and of 
important relevance to humans, was not oxidized to its metabolite 7-hydroxymethotrexate 
by partially purified bovine kidney aldehyde oxidase based on our limited experimental 
work.  This then indicates that the aldehyde oxidase enzyme from bovine kidney does not 
contribute to the oxidation of this xenobiotic thereby not contributing to cytotoxicity of 
the bovine kidney cells by 7-hydroxymethotrexate.  However, this work does show that 
bovine liver and rabbit liver aldehyde oxidase do contribute to the cytotoxicity of liver 
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cells by catalyzing  the oxidation of methotrexate to 7-hydroxymethotrexate.  In earlier 
work by Aya Moriyasu et. al. (36) and S. Kitamura et. al. (55) it was shown that 
methotrexate is converted to 7-OH-MTX by rat liver aldehyde oxidase also. 
 The inhibition studies performed showed that the oxidation of phenazine 
methosulfate by bovine kidney aldehyde oxidase was inhibited by methanol but not by 
menadione.  However, the oxidation of phenazine methosulfate by rabbit liver aldehyde 
oxidase was inhibited by both methanol and menadione.  In a similar experiment by 
David G.Johns (31) it was found that menadione was ineffective at inhibiting the 
phenazine methosulfate oxidation reaction by human liver aldehyde oxidase although it 
was effective at inhibiting rabbit liver aldehyde oxidase by about 58% at a menadione 
concentration of 2.5x10
-5
M for the same reaction (31).   Our study showed a 54% 
inhibition of the phenazine methosulfate oxidation by rabbit liver aldehyde oxidase at a 
menadione concentration of 9.1x10
-5
M.  Those results were not what are expected due to 
the fact that menadione has proven to be a potent AO inhibitor and in most cases usually 
eliminating all or nearly all AO activity for that particular substrate.  In an experiment 
conducted by Yoshihara and Tatsumi (56), a 0.5 µM and 1.0 µM concentration of 
menadione inhibited the oxidation of benzaldehyde by mouse liver aldehyde oxidase to 
91% and 96% respectively.  In another experiment by S. Kitamuro et al. (55) an 84% 
inhibition of the oxidation of methotrexate by the purified rat liver aldehyde oxidase was 
shown.  Though the methanol inhibitor was able to inhibit the phenazine methosulfate 
oxidation reaction by all three tissues it did not do so very effectively.  In a work by 
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David G. Johns (31) where they used a different oxidation reaction, it was shown that a 
0.3M concentration of methanol inhibited the oxidation of benzaldehyde to benzoic acid 
by human liver aldehyde oxidase by 67%.  This research only showed a 30% and 6% 
inhibition of the oxidation of phenazine methosulfate by the bovine aldehyde oxidases 
and rabbit liver aldehyde oxidase, respectively.  The inhibition data above indicates that 
the oxidation of phenazine methosulfate is not as sensitive to menadione and methanol 
inhibition than to other oxidation reactions.  However, the inhibition data was consistent 
with other similar experimental work which helps verify that aldehyde oxidase was the 
enzyme responsible for the activity values measured.   Inhibition studies using other 
substrate oxidations such as N
1
-methylnicotinamide, would be valuable experiments and 
help to better characterize the bovine tissue enzymes. 
 The evaluation of the purification procedure showed typical and expected results.  In 
normal cases, as an enzyme purification procedure progresses, the enzyme activity also 
increases since the enzyme becomes more pure.  The percent yield however, decreases 
mainly due to enzyme loss at different points in the procedure.  Our evaluation showed a 
2-fold increase in bovine kidney xanthine oxidase activity when comparing the heat 
treatment step to the crude homogenate and a 5-fold increase when comparing the 50% 
ammonium sulfate fraction to the crude homogenate.  In a paper by J.G.P. Stell, A.J. 
Warne, and C. Lee-Woolley (57), they also stated that there is an approximate 6-fold gain 
in specific activity at the ammonium sulfate precipitation step.  They also state that at this 
step there is little loss in enzyme activity (57).  In another similar experiment by Maia 
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and Mira (1), a 2-fold increase in rat liver xanthine oxidase was observed when 
comparing the heat treatment step to the crude homogenate and a 9-fold increase when 
comparing a 60% ammonium sulfate fraction to the crude homogenate.  For aldehyde 
oxidase activity, Maia and Mira (1) found a 3.2-fold increase in the rat liver enzyme 
when comparing a 60% ammonium sulfate fraction to the heat treated sample.  Our 
results showed a 1.3-fold increase when comparing the 50% ammonium sulfate fraction 
to the heat treated sample for the bovine kidney enzyme.  These results and comparisons 
indicate that our technique for the purification procedure was effective, efficient and 
comparable to the work of other researchers. 
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